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The Interaction Properties
of Costimulatory Molecules Revisited
and their receptors, CD28 and CTLA-4 (CD152) ex-
pressed by T cells (reviewed by Lenschow et al., 1996).
An additional CD28-like molecule, ICOS (Hutloff et al.,
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ing studies (Brodie et al., 2000) and the analysis of trans-The University of Oxford
genic mice (Mandelbrot et al., 1999) indicate that B7-1John Radcliffe Hospital
and B7-2 are the only functional ligands of CD28 andHeadington
CTLA-4. CD28 is constitutively expressed on most rest-Oxford OX3 9DU
ing human T cells, and B7-2 is rapidly induced on anti-2 Sir William Dunn School of Pathology
gen-presenting cells early in immune responses. TheThe University of Oxford
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after a delay of 24–48 hr, however (reviewed byOxford OX1 3RE
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as covalent homodimers of single V-set immunoglobulinThe University of Oxford
superfamily (IgSF) domains, whereas B7-1 and B7-2Roosevelt Drive
each consist of single V-set and C1-set IgSF domainsOxford OX3 7BN
(reviewed by Lenschow et al., 1996; Ikemizu et al., 2000).4 Oxford Centre for Molecular Sciences
It is clear that CTLA-4 binds bivalently to B7-1 and B7-2The University of Oxford
(Schwartz et al., 2001; Stamper et al., 2001), but theNew Chemistry Laboratory
stoichiometry of CD28 interactions is poorly defined.South Parks Road
Crystallographic and solution studies indicate that solu-Oxford OX1 3QT
ble (s) B7-1 tends to dimerize, prompting the suggestionUnited Kingdom
that, at the cell surface, the interactions of B7-1 might be5 Active Biotech Research AB
avidity-enhanced by the formation of two-dimensionalScheeleva¨gen 22363, Lund
arrays in which B7-1 homodimers are bridged by biva-Sweden
lent ligand (Ikemizu et al., 2000). The affinity of sB7-1
self-association is consistent with B7-1 existing at the
cell surface in a dynamic equilibrium dominated by the
dimer (Ikemizu et al., 2000).Summary
CD28 belongs to a group of molecules that “costimu-
late” T cells. In the absence of such signals, T cellsB7-1 and B7-2 are generally thought to have compara-
enter an anergic state (reviewed by Jenkins, 1994). CD28ble structures and affinities for their receptors, CD28
signaling synergizes with that of the T cell receptor (TCR)and CTLA-4, each of which is assumed to be bivalent.
to induce cell proliferation and cytokine secretion. Spe-
We show instead (1) that B7-2 binds the two receptors
cifically, CD28 and TCR signals intersect in a Vav1-
more weakly than B7-1, (2) that, relative to its CTLA-4
dependent manner before inducing the binding of
binding affinity, B7-2 binds CD28 2- to 3-fold more NF-B/Rel- and AP-1-family transcription factors to a
effectively than B7-1, (3) that, unlike B7-1, B7-2 does composite CD28 response element in the IL-2 promoter
not self-associate, and (4) that, in contrast to CTLA-4 (Shapiro et al., 1997; Hehner et al., 2000). CD28 also
homodimers, which are bivalent, CD28 homodimers stabilizes IL-2 mRNA and enhances T cell survival by
are monovalent. Our results indicate that B7-1 mark- increasing the expression of the antiapoptotic protein,
edly favors CTLA-4 over CD28 engagement, whereas Bcl-xL (Lindstein et al., 1989; Boise et al., 1995). Finally,
B7-2 exhibits much less bias. We propose that the the pro-signaling microenvironment of the immunologi-
distinct structures and binding properties of B7-1 and cal synapse is enhanced by the recruitment of cell sur-
B7-2 account for their overlapping but distinct effects face molecules and kinase-rich rafts in response to co-
on T cell responses. stimulatory signaling (Wu¨lfing and Davis, 1999; Viola et
al., 1999). CTLA-4 engagement, on the other hand, in-
Introduction duces powerful inhibitory signals in T cells as is best
illustrated by the severe lymphoproliferative disorder to
Immune responses are profoundly influenced by protein which CTLA-4-deficient mice succumb shortly after
interactions involving leukocyte cell surface proteins. birth (Waterhouse et al., 1995). CTLA-4 attenuates lck,
Prominent among these are the B7 ligands, B7-1 (CD80) fyn, and ZAP-70 activation and has been linked to de-
and B7-2 (CD86) expressed on antigen-presenting cells, phosphorylation of the  chain of CD3 (Marengere et al.,
1996; Lee et al., 1998). Other data suggest that CTLA-
4 inhibits T cell activation, at least in part, by competing6 Correspondence: anton.vandermerwe@path.ox.ac.uk (P.A.v.d.M.),
with CD28 for ligands on antigen-presenting cells (Mas-sdavis@molbiol.ox.ac.uk (S.J.D.)
7 These authors contributed equally to this work. teller et al., 2000). In addition to these proximal effects
Immunity
202
on signaling, CTLA-4 may mediate its inhibitory effects
indirectly, possibly by enhancing the generation of regu-
latory CD25 T cells (Bachmann et al., 1999; Read et
al., 2000; Takahashi et al., 2000).
Although the activating and inhibitory functions of
CD28 and CTLA-4 ligation are well established, the re-
quirement for the two sequentially expressed ligands,
B7-1 and B7-2, is poorly understood. It is clear that the
genes encoding B7-1 and B7-2 arose via duplication of
a common precursor and that the functions of B7-1
and B7-2 overlap considerably (see, e.g., Borriello et al.,
1997). The preservation of both genes in all mammals
examined, however, strongly suggests that the two
genes have been subjected to distinct selection pres-
sures. Moreover, numerous studies have documented
the differential effects of anti-B7-1 and anti-B7-2
blocking antibodies on immune responses both in vitro
and in animal models (reviewed by Lenschow et al.,
1996; Salomon and Bluestone, 2001). Nevertheless,
there is little consensus regarding whether or not B7-1
and B7-2 have distinct regulatory functions and even
less agreement on what these functions might be.
At least part of the explanation for this is that there
has been no obvious molecular basis for large functional
differences, given that the interactions of costimulatory
molecules are generally thought to have relatively uni-
form properties, i.e., that B7-1 and B7-2 have similar
structures and affinities for CD28 versus CTLA-4 and
Figure 1. Characterization of sB7-2
that CD28 and CTLA-4 are both bivalent (see Sharpe
(A) SDS-PAGE analysis of sB7-2 under reducing (R) and nonreducing
and Freeman, 2002 and Carreno and Collins, 2002, for (NR) conditions. Distances that reduced molecular weight markers
the prevailing view). We show here that costimulatory migrated are indicated.
receptors and their ligands in fact form signaling com- (B) Depletion of a solution of purified sB7-2 (lane 1) by Ni-NTA-
coupled agarose beads (Qiagen) (lane 2), Sepharose 4B beads aloneplexes of unexpected structural diversity, whose stabili-
(lane 3), or by monoclonal antibodies, BU63 (lane 4), and FUN-1ties vary by more than four orders of magnitude. Our
(lane 5), attached via protein A to Sepharose 4B beads. The visibleresults are consistent with a model of T cell costimula-
bands present in lanes 4 and 5 appear to be the heavy and lighttion in which the distinct structures and binding proper-
chains of antibody dissociating from the beads.
ties of B7-2 and B7-1 significantly enhance the activat- (C) Elution of sB7-2 from a Sephadex S-200 gel-filtration column.
ing and inhibitory functions of CD28 and CTLA-4, The elution positions of size calibration markers are indicated.
respectively.
Results Analysis of sB7-2 Solution Properties by AUC
Deglycosylated sB7-1 forms a homodimer when crystal-
Expression of sB7-2 lized alone (Ikemizu et al., 2000), as does fully glycosy-
Soluble, histidine-tagged B7-2 (sB7-2) was expressed in lated sB7-1 in solution and in crystal lattices when com-
Chinese hamster ovary (CHO) cells using the approach plexed with CTLA-4 (Ikemizu et al., 2000; Stamper et al.,
followed for sB7-1 (van der Merwe et al., 1997). Trunca- 2001). An unglycosylated form of B7-2, consisting of
tion of the protein at Pro-224 yielded a product con- the ligand binding domain, forms asymmetric, back-to-
sisting of the intact extracellular region of B7-2. In reduc- back lattice contacts when cocrystallized with CTLA-4
ing and nonreducing SDS-PAGE gels, sB7-2 migrated (Schwartz et al., 2001). We therefore examined, using
as a broad band of 45–60 kDa (Figure 1A), consistent AUC, whether fully glycosylated sB7-2 produced in CHO
with heavy glycosylation (at up to eight sites). The sB7-2 cells is able to self-associate in solution. In equilibrium
was completely depleted from solution by conforma- experiments at 37C, neither sB7-2 (Figure 2A) nor the
tion-sensitive, noncompeting anti-B7-2 monoclonal an- ICOS ligand, LICOS (Figure 2B), formed dimers or other
tibodies (mAbs: BU63 and FUN-1; Figure 1B) and crystal- oligomeric species. This conclusion was supported by
lized (data not shown), implying that all of the purified sedimentation velocity experiments (data not shown)
protein was correctly folded. CD28 and CTLA-4, ex-
and gel-filtration analyses (e.g., Figure 1C). These results
pressed as chimeras with human IgG Fc (designated
indicate that, in contrast to B7-1, the extracellular do-
CD28Fc and CTLA-4Fc, respectively), are characterized
main of glycosylated B7-2 does not self-associate.elsewhere (van der Merwe et al., 1997). A second
CD28Fc chimera, consisting of the entire extracellular
Stoichiometry of CD28Fc Interactionsregion of CD28 (inclusive of the native, interchain disul-
with sB7-1 and sB7-2fide), a thrombin-cleavable site, and murine IgG Fc, will
Early binding experiments (Linsley et al., 1995) and sub-be described elsewhere (R.M.-S. et al., unpublished
data). sequent structural studies of CTLA-4/B7 complexes
Comparing B7-1 and B7-2 Binding to CD28 and CTLA-4
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Figure 2. AUC Analysis of sB7-2 and sLICOS
Molecular weights for sB7-2 (A) and sLICOS
(B), determined from AUC equilibrium experi-
ments, plotted against protein concentration.
(Stamper et al., 2001; Schwartz et al., 2001), have dem- immobilized CD28 or CTLA-4, this was determined by
subsequently injecting saturating amounts of CD28- andonstrated unequivocally that the CTLA-4 homodimer is
bivalent. While it is often assumed that the CD28 homo- CTLA-4-specific Fab fragments. When normalized for
the level of Fab binding (sB7-1 binding/Fab binding),dimer is also bivalent (Greene et al., 1996), this has never
been directly demonstrated. We therefore analyzed the it was evident that CTLA-4 bound twice the amount of
sB7-1 than was bound by the equivalent level of CD28.CD28 binding stoichiometry using surface plasmon res-
onance as implemented in the BIAcore. We compared Importantly, the CTLA-4 Fab bound CTLA-4Fc that had
been captured onto the BIAcore surface by the samethe amount of sB7-1 that bound to given amounts of
CD28Fc and CTLA-4Fc immobilized onto the BIAcore Fab, indicating the presence of two epitopes on the
CTLA-4Fc, as expected; similarly, the CD28 Fab wassensor surface (Figure 3A). A saturating amount of sB7-1
was injected over flow-cells in which CD28Fc, CTLA- shown to have two epitopes on CD28Fc (data not
shown). Furthermore, the same 2-fold higher level of4Fc, and a control protein were each immobilized. The
difference in the level of the response in the CD28Fc or sB7-1 binding to CTLA-4 versus CD28 was observed
when the normalization was performed with eight differ-CTLA-4Fc flow-cells versus the control flow-cells repre-
sented the maximum level of sB7-1 binding. Since the ent CD28 antibodies and three different CTLA-4 antibod-
ies (data not shown). These controls indicate that thelevel of sB7-1 binding depends on the level of active
Figure 3. Stoichiometry of CD28 versus
CTLA-4 Interactions
(A) A saturating amount of sB7-1 (42M, solid
bar) was injected through flow-cells in which
CD28Fc (dashed line), CTLA-4Fc (dotted line),
or CD22Fc (solid line) had been immobilized
indirectly at 1529, 1703, and 1510 RUs, re-
spectively. Following complete dissociation
of sB7-1, 9.3 Fab (anti-CD28) and 11D4 Fab
(anti-CTLA-4) were injected (solid bars)
through all three flow-cells at saturating con-
centrations (50g/ml). The amount of binding
of sB7-1 was calculated by subtracting the
background response in the CD22Fc flow-
cell from the responses in the CD28Fc and
CTLA-4Fc flow-cells. In the representative
example shown, the ratio of CTLA-4/11D4
Fab binding (870 RU/1520 RU 0.57) is dou-
ble that for CD28/9.3 Fab binding (205 RU/
740 RU  0.28).
(B) CD28Fc (4.3 M, solid lines) and sCD28
(20.1 M, dotted lines) were injected (solid
bar) over a flow-cell containing directly immo-
bilized sB7-1 (heavy lines) or control CD22Fc
(light lines). Inset: For equilibrium binding
analysis of the affinity of sCD28 for sB7-1,
sCD28 was injected at a range of concentra-
tions (44 M and 4/3-fold dilutions thereof)
for 30 s at 10 l/min.
(C) CTLA-4Fc (3 M) was injected (solid bar)
over the flow-cells containing directly immo-
bilized sB7-1 (heavy line) or control CD22Fc
(light line).
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Figure 4. Equilibrium Binding Analyses
(A) sB7-2, at a range of concentrations (251
M and 4/3-fold dilutions thereof) was in-
jected at 10 l/min sequentially (solid bar)
through a flow-cell containing 2200 RU of in-
directly immobilized CD28Fc at 37C. Back-
ground responses observed in a control flow-
cell containing immobilized CD22Fc were
subtracted from the total responses to give
binding (solid lines).
(B) Nonlinear curve fitting of the untrans-
formed data using a 1:1 Langmuir binding
isotherm yielded a Kd of 19.1 M and a bind-
ing maximum of 203 RU. A linear Scatchard
plot of the CD28/B7-2 binding data (inset)
yielded the same Kd and binding maximum.
(C) sB7-2, at a range of concentrations (251
M and 4/3-fold dilutions thereof) was in-
jected as in (A) through a flow-cell containing
800 RU of indirectly immobilized CTLA-4Fc
at 37C. Background responses have been
subtracted.
(D) Nonlinear curve fitting of the untrans-
formed binding data using a 1:1 Langmuir
binding isotherm (dashed line) gives a worse
fit than a fixed, two-site binding model (solid
line). The two-site model yielded high- and
low-affinity Kd values of 3.2 and 25.8 M, re-
spectively. A Scatchard plot of the data (inset)
was clearly nonlinear.
observed stoichiometry is not an artifact of an unusual et al., 1997). In conclusion, the binding properties of
sB7-1 binding to CD28 homodimer are independent ofantibody epitope. Significantly, there was also a 2-fold
higher level of sB7-2 binding to CTLA-4Fc versus the binding orientation, consistent with a 1:1 binding
stoichiometry. In contrast, sB7-1 binds with a higherCD28Fc (data not shown), indicating that this difference
in stoichiometry is identical for both sB7-1 and sB7-2. avidity to CTLA-4 when sB7-1 is immobilized, consistent
with a 1:2 CTLA-4Fc:sB7-1 stoichiometry. ICOSFc:sLICOSThese results, taken together with the known (2:1)
stoichiometry of B7 binding to the CTLA-4 homodimer, binding exhibited the same orientation dependence as
CTLA-4Fc:sB7-1 interactions (data not shown), sug-indicate that only one B7 molecule binds a CD28 homo-
dimer. If correct, this conclusion predicts that a soluble gesting that this interaction also has a 1:2 stoichiometry.
CD28 homodimer, because it is monovalent, would bind
with the same properties to immobilized B7 as soluble Affinity Measurements
The affinity and kinetic properties of sB7-2:ligand inter-B7 binds to immobilized CD28. To test this prediction,
CD28Fc and CTLA-4Fc were injected over immobilized actions were also characterized using the BIAcore, with
all experiments performed at 37C except where indi-sB7-1 (Figures 3B and 3C). CD28Fc binding to immobi-
lized sB7-1 displayed the same rapid kinetics observed cated. The affinities were determined by equilibrium
binding as this avoids pitfalls, such as mass-transportwhen this interaction was studied in the reverse orienta-
tion (van der Merwe et al., 1997), reaching equilibrium limitations and rebinding, which commonly affect kinetic
measurements. To this end, sB7-2 at a wide range ofwithin 10 s, and dissociating rapidly at the end of the
injection (Figure 3B). In contrast, CTLA-4Fc bound im- concentrations was injected sequentially over immobi-
lized CD28Fc or CTLA-4Fc (Figures 4A and 4C showmobilized sB7-1 with a much higher avidity than ob-
served in the reverse orientation (van der Merwe et al., overlays of the binding observed with the full range of
sB7-2 concentrations). Binding reached equilibrium very1997), dissociating with a half-life (t1/2)  200 s (Figure
3C) instead of 2 s (van der Merwe et al., 1997). quickly (95% binding within 1–3 s) following the onset
of the injection, and, when the injection ended, sB7-2In order to exclude an effect of the Fc region on the
binding properties of the CD28, we also analyzed the dissociated very rapidly, with near complete dissocia-
tion within 15 s (Figures 4A and 4C). A plot of the bindingbinding of CD28 homodimer (sCD28) from which the Fc
had been removed. sCD28 and CD28Fc bound with at equilibrium versus concentration indicated that the
binding of sB7-2 to both CD28Fc and CTLA-4Fc wasidentical fast kinetics (Figure 3B). The affinity of sCD28
binding was measured by determining the binding at saturable (Figures 4B and 4D). For the sB7-2:CD28Fc
binding data, an excellent fit of the 1:1 (Langmuir) bind-equilibrium of sCD28, at a range of concentrations, to
immobilized sB7-1. A Scatchard plot of these data is ing isotherm (Figure 4B) was obtained by nonlinear curve
fitting, and a Scatchard plot of the same data was linearlinear (Figure 3B, inset), consistent with 1:1 binding, and
gave a Kd value of 4.2 	 0.9 M (mean 	 SD, n  5), in (Figure 4B, inset). Thus, the binding conformed to the
Langmuir binding model, and this indicated that bothexcellent agreement with the Kd (4 M) measured for
sB7-1 binding to immobilized CD28Fc (van der Merwe sB7-2 and CD28 were homogenous with a single type
Comparing B7-1 and B7-2 Binding to CD28 and CTLA-4
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of binding site. Successive, independent measurements be excluded if it is shown that decreasing the level of
immobilized ligand does not result in an increase in theyielded Kd values of 20 	 2 M (mean 	 SD, n  4),
which is about 5-fold lower than the affinity measured apparent rate constants.
CTLA-4Fc:sB7-2 Bindingfor sB7-1 binding to CD28.
In contrast to the results obtained for sB7-2:CD28 Dissociation rate constants (koff) were determined follow-
ing the injection of sB7-2 at a range of concentrationsbinding, the sB7-2:CTLA-4Fc binding data did not con-
form to the Langmuir binding model (Figure 4D). This is (Figure 5B). Good fits were obtained with a single expo-
nential decay model, consistent with a single koff valueevident in the poor nonlinear fit of the model to the
untransformed binding data (Figure 4D) and the devia- (5.1 	 0.8 s
1 [mean 	 SD, n  7]). Importantly, this
koff was the same irrespective of the concentration attion from linearity of the Scatchard plot of the same
data (Figure 4D, inset). There are numerous possible which the sB7-2 was injected (Figure 5B). These findings
indicate that the CTLA-4 binding sites are homogenousmechanisms that could account for such a result, includ-
ing heterogeneity of sB7-2 and/or CTLA-4, or self-asso- with respect to their koff. In separate experiments, we
showed that the apparent koff did not vary substantiallyciation of sB7-2. The fact that an excellent fit to the
Langmuir model was observed with the same sB7-2 when the level of immobilized CTLA-4 was varied around
the values used for these measurements, ruling outpreparation binding to immobilized CD28Fc argues
strongly against heterogeneity of sB7-2. Furthermore, mass-transport or rebinding artifacts (data not shown).
Association-rate constants (kon) were determined byas shown above, we were unable to detect any sB7-2
self-association. Thus, the most plausible explanation nonlinear curve fitting of the simple 1:1 Langmuir associ-
ation model to injection-phase data using koff valuesfor the observed binding is heterogeneity of CTLA-4.
Trivial explanations for CTLA-4 heterogeneity such as obtained from analysis of the corresponding dissocia-
tion phase (Figure 5A). Although reasonable fits wereaggregation of CTLA-4 Fc or heterogeneous immobiliza-
tion are unlikely since neither gel-filtration of the CTLA- obtained, the small number of data points available for
each fit before equilibrium is attained make it impossible4Fc immediately prior to immobilization nor indirect
immobilization by an anti-Fc antibody eliminated this to assess from individual fits whether the kon values are
heterogenous. However, the finding that, unlike the koffheterogenous binding.
One possible source of the heterogeneous binding is determinations, the measured apparent kon values varied
substantially with the concentration at which the sB7-2the presence of two binding sites on a single CTLA-4Fc
homodimer, each with distinct properties. Consistent was injected (Figure 5 legend), is evidence that the kon
is indeed heterogeneous. At the lowest sB7-2 concen-with this, a simple two-site binding model gave a much
better fit to the data than the one-site model (Chi2  1.8 tration (6.5 M), the apparent kon was 4-fold faster than
at the highest sB7-2 concentration (105 M; Figure 5versus 167 for two-site versus the one-site fits, Figure
4D, solid versus dashed line), and, in multiple fits, each legend). Since at low sB7-2 concentrations binding will
primarily be to high-affinity sites whereas at higher con-site was at approximately a 1:1 ratio (1:1.22 for the fit
shown in Figure 4D). The high- and low-affinity sites had centrations binding will be to both high- and low-affinity
sites, this indicates that the low- and high-affinity bind-Kd values of 2.6	 0.5 M (mean	 SD, n 3) and 22.4	
3 M (mean 	 SD, n  3), respectively. Further support ing sites identified by equilibrium affinity measurements
have similar koff values but differ in their kon values.for a difference in the affinity between the two binding
sites on the CTLA-4 homodimer was provided by re- CD28Fc:sB7-2 Binding
sB7-2 dissociated extremely rapidly from immobilizedanalysis of previously published sB7-1 binding data (van
der Merwe et al., 1997). While sB7-1 binding to CD28Fc CD28Fc such that the koff was at the very limit of detec-
tion for the BIAcore. Several independent determina-fitted well to the Langmuir model, binding to CTLA-4Fc
fitted significantly better to the simple two-site (Chi2  tions gave a mean apparent koff value of 31 	 2 (mean 	
SD, n  4; e.g., Figure 5C), a value that is indistinguish-3.3) than to the one-site (Chi2  56) binding models and
gave affinities for the two sites also differing 7-fold in able from the theoretical wash rate at that flow rate (28
s
1; Davis et al., 1998). Consequently, these rates mustmagnitude: 0.2 M and 1.4 M (data not shown). While
the binding heterogeneity makes the comparison be- be considered to be the lower limit of the true koff (i.e.,
koff  28 s
1). Binding was far too fast for the kon to between B7-2 and B7-1 difficult, it is evident that B7-2
binds with a 10- to 20-fold lower affinity than B7-1 to measured directly. However, taking the koff to be  28
s
1 and the Kd (determined by equilibrium binding analy-CTLA-4.
These results indicate that sB7-2 and sB7-1 binding sis) to be 20 M, the kon can be calculated to be  1.4 
106 M
1s
1 at 37C.to CD28 is homogeneous whereas binding to CTLA-4 is
heterogeneous. Affinity measurements of LICOS binding
to immobilized ICOSFc, which appears to be bivalent, Discussion
exhibited the same type of heterogeneity as B7 binding
to immobilized CTLA-4Fc (data not shown). The key findings of this study are summarized, along
with the results of our previous analyses (van der Merwe
et al., 1997; Ikemizu et al., 2000), in Figure 6. In dis-Kinetic Measurements
Measurements of binding kinetics are more prone to cussing these results, we assume that the magnitude
of the affinity differences we observe in solution applyerror than equilibrium measurement, largely because of
the problems of mass-transport limitations and rebind- equally to the equivalent interactions at the cell surface,
as can be argued on theoretical grounds (Bell, 1978).ing of dissociated analyte, which can lead to the under-
estimation of binding rate constants. These artifacts can Our results indicate that B7-2 and B7-1 differ in three
Immunity
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Figure 6. Summary of Organization and Binding Properties of Sig-
naling Complexes Formed by CD28, CTLA-4, B7-1, B7-2, ICOS, and
LICOS
(A) Proposed structural changes to B7 family (B7F) and CD28 family
(CD28F) proteins in the course of their evolution. Gene duplication
and sequence divergence yielded monomeric and homodimeric,
low- and high-affinity forms of the B7 family. Similarly, gene duplica-
tion and structural rearrangements (see Figure 7) generated low-
affinity monovalent and high-affinity bivalent members of the CD28
family. The proposed precursors (boxed) are based on the properties
of the avian homologs of these proteins (i.e., chicken CD28 and
chCD80L; D.W.B. and J. Young, unpublished data).
(B) Quaternary structures and binding properties of the signaling
complexes formed by human CD28, CTLA-4, B7-1, B7-2, ICOS, and
LICOS. The averaged affinities and measured or calculated kinetic
constants for each interaction are also shown. The high- and low-Figure 5. Kinetic Analysis of sB7-2 Binding to CTLA-4Fc and
affinity values shown for CTLA-4 interactions are for the two sitesCD28Fc
revealed by equilibrium binding analysis; only kinetic data relevant
(A) Nonlinear curve fitting of association data for sB7-2 injected at to the high-affinity binding site are presented. Data for B7-1 and
6.5 M, 26 M, and 105 M over 1000 RU of directly immobilized LICOS interactions are from van der Merwe et al. (1997) and Brodie
CTLA-4Fc at 37C. The data were fitted with standard 1:1 association et al. (2000). N.D., not determined.
models, giving kon values of 1.6  105, 3.2  105, and 6.5  105
M
1s
1 when sB7-2 was injected at 105, 26, and 6.5M, respectively.
(B) sB7-2, at concentrations of 3M, 13M, and 26M, was injected with B7-1, are unlikely to be avidity-enhanced by the
at 100 l/min at 37C over 1000 RU of directly immobilized CTLA- formation of bivalent B7-2 homodimers capable of
4Fc and allowed to dissociate at the end of each injection. Data
bridging CTLA-4 homodimers. Third, relative to itswere recorded at the maximal collection rate (10 Hz) until the re-
CTLA-4 binding affinity, B7-2 binds CD28 2- to 3-foldsponse had returned to baseline. Responses in a control flow-cell
more effectively than B7-1 (i.e., the CD28/CTLA-4 Kdwere subtracted and the remaining binding plotted as a percentage
of initial binding. The data are fitted with single exponential decay ratios are 8 and 20 for B7-2 and B7-1, respectively).
curves, giving koff values of 5.1 	 0.8 s
1 (mean 	 SD, n  7). In other words, relative to B7-1, the binding of B7-2 is
(C) Dissociation of sB7-2 from CD28Fc at 37C. sB7-2 (156 M) was biased against CTLA-4. The consequence of this is that,
injected over 1226 RU of immobilized CD28Fc at 100 l/min. The
all other things being equal, when B7-2 is expressed ondata are fitted with a single exponential decay curve yielding a koff
an APC, the ratio of engaged CD28 to engaged CTLA-4value of 29.3 s
1.
at the T cell:APC interface will be higher than when B7-1
is expressed. Activating signals elicited by B7-2:CD28
interactions are therefore less likely to be attenuated bykey respects, each of which will markedly affect the
signaling properties of CD28 and CTLA-4. First, B7-2 coincident CTLA-4 ligation than those elicited by B7-1,
enhancing the costimulatory effects of B7-2 when CD28binds 13-fold more weakly to CTLA-4 than B7-1. Sec-
ond, CTLA-4 interactions with B7-2, in contrast to those and CTLA-4 are coexpressed. Conversely, inhibitory sig-
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Figure 7. Surface Residue Conservation in CD28 and CTLA-4
In (A) through (C), a single view of the crystal structure of the CTLA-4 monomer is shown (Stamper et al., 2001). The line of view is parallel
with the  sheets, with the ligand binding surface facing to the right and the COOH terminus at the base. Residues completely conserved in
all CTLA-4 and CD28 homologs are colored blue. In (A), residues conserved in all CTLA-4 homologs and substituted in one or more of the
CD28 homologs are colored pink. In (B), residues mediating CTLA-4 homodimerization (a subset of those colored pink in (A)) are colored red.
In (C), CD28-equivalent residues conserved in all CD28 homologs and substituted in one or more of the CTLA-4 homologs are colored yellow.
The absence in CD28 of any conservation of the residues mediating the formation of CTLA-4 homodimers suggests that CD28 may self-
associate into homodimers that are structurally distinct from those of CTLA-4.
naling by B7-1 will be enhanced under the same circum- foundly alter the course of disease in these TH1-depen-
dent models, however. These issues will be discussedstances. Taken together, these results indicate that B7-1
interactions with CTLA-4 will be markedly favored over at length elsewhere.
Whereas the present study indicates that the struc-interactions with CD28 and that B7-2 will exhibit much
less bias. We conclude, therefore, that the delayed ex- tures and ligand binding properties of B7-1 and B7-2 are
very different, others have emphasized their similarities.pression of B7-1 is timed to specifically enhance inhibi-
tory signaling by CTLA-4. Linsley et al. (1994) concluded on the basis of multivalent
assays that B7-1 and B7-2 bind with similar avidities toThe concept that, by preferentially engaging CTLA-4,
B7-1 is predominantly but not exclusively inhibitory, CD28 versus CTLA-4. We note, however, that assays
of this type will inevitably tend to conceal real affinitywhereas B7-2 is costimulatory due to more effective
interactions with CD28, is compatible with a number of differences. Similarly, Schwartz et al. (2001) proposed
that B7-2 forms B7-1-like homodimers on the basis ofstudies in which the properties of B7-1 and B7-2 have
been compared. We cite just a few in vivo experiments lattice contacts observed in crystals of bacterially ex-
pressed B7-2 domain 1:CTLA-4 complexes. While su-as examples: (1) treatment of NOD mice with blocking
anti-B7-2 mAb protects from diabetes whereas blocking perficially similar to sB7-1 homodimers, the B7-2 homo-
dimers and CTLA-4:B7-2 interfaces were structurallyanti-B7-1 accelerates the disease process in female
mice and induces diabetes in normally resistant males asymmetric, contrary to the expectation that organized,
self-assembled structures form via identical subunit(Lenschow et al., 1995); (2) antigen-dependent expan-
sion of adoptively transferred, transgenic CD4 T cells interactions (Klug, 1969). Unconstrained, asymmetric
structures, such as those proposed to form at the cellis enhanced by anti-B7-1 mAb and partially inhibited by
anti-B7-2 (Kearney et al., 1995); (3) in a murine model surface for B7-2, will fail to efficiently self-assemble be-
cause lower-energy conformations will always be fa-of allo-transplantation, B7-1 and CTLA-4 are necessary
for tolerance induction whereas B7-2 is required for acti- vored over higher-energy states. We predict that native
sB7-2 does not dimerize because it is glycosylated atvation of the allo-reactive T cells (Judge et al., 1999);
and (4) B7-2-deficient mice have milder kidney damage the base of the dimer interface proposed by Schwartz
et al. (2001) (i.e., at Asn-8). This site will be unglycosy-than wild-type mice, in contrast to B7-1-deficient mice
which have more severe damage in a murine systemic lated in bacterially expressed protein, implying that the
B7-2 homodimers are artifacts of crystallization.erythematosis model (Liang et al., 1999). We acknowl-
edge, however, that in some systems B7-2 blockade The observation that CD28 homodimers are monova-
lent whereas CTLA-4 is bivalent was unexpected givenenhances immune responses and that anti-B7-1 anti-
bodies are inhibitory. For example, experimental allergic the generally accepted view that these molecules are
each bivalent (see, e.g., Sharpe and Freeman, 2002;encephalomyelitis, autoimmune uveoretinitis, and cres-
centic glomerulonephritis are all more severe in anti- Carreno and Collins, 2002). Greene et al. (1996) were
the first to propose two-site binding models for bothB7-2 than anti-B7-1 mAb-treated mice (Kuchroo et al.,
1995; Fukai et al., 1999; Li et al., 2000). Restricting or CTLA-4 and CD28. Crucially, however, Greene et al.
were uncertain whether their CD28 preparation was di-enhancing the development of protective TH2 re-
sponses, by interfering with the preferential interactions meric or tetrameric. This is important as the presence of
even small amounts of bivalent tetramers would accountof CD28 and CTLA-4 with B7-2 and B7-1, may pro-
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for the CD28 binding heterogeneity observed in their ences between CD28 and CTLA-4 is unresolved. One
experiments. possibility is suggested by our analysis of B7:CTLA-4
The effect of bivalency on the avidity of interacting cell interactions, which shows that B7 proteins bind with
surface molecules is difficult to measure or calculate. A two on-rates and a single off-rate. The simplest explana-
reasonable guide, based on the solution off-rates for the tion for this is that the two binding sites are equivalent
binding of monovalent versus bivalent forms of CTLA-4 but that binding of the first B7 molecule to CTLA-4 re-
to immobilized sB7-1, is that bivalent binding is approxi- duces the on-rate for binding of the second. The struc-
mately two orders of magnitude more stable than mono- tures of B7:CTLA-4 complexes (Schwartz et al., 2001;
valent binding (the t1/2 values for the dissociation of Stamper et al., 2001) reveal that the B7 molecules bind
monomeric CTLA-4 and CTLA-4Fc from immobilized in the same plane and parallel to one another, allowing
sB7-1, are 2 s [data not shown] and 200 s [Figure steric interference with association of the second mole-
3C], respectively). Overall, the monovalent affinities of cule. Since the MYPPPY sequence at the heart of the
interactions within this system vary up to 100-fold in binding face is conserved in both CD28 and CTLA-4, it
magnitude (i.e., from low-affinity B7-2:CD28 interactions is very likely that the B7 proteins bind CD28 monomers
of Kd  20 M to high-affinity B7-1:CTLA-4 interactions in much the same way. However, the two monomers
of Kd  0.2 M). The effects of bivalent binding by might be organized differently in CD28, exaggerating
CTLA-4 will extend this range of stabilities, perhaps by the interference seen in CTLA-4 interactions, to the ex-
two orders of magnitude. Bivalent B7-1 interactions will tent that binding of a second B7 molecule is completely
further enhance these effects. The sequential expres- prevented. Consistent with this possibility, we note that
sion of B7-2 and B7-1, allied with these quaternary struc- the most conserved surface residues outside the bind-
tural and affinity differences, are therefore likely to effect ing face of CD28 map not to the base of the A- and G-
10,000-fold differences in the half-lives of these strands, which, along with a disulphide bond, mediate
closely related signaling complexes. CTLA-4 homodimerization (Figures 7A and 7B), but to
Why might such profound changes in the stability of the top of these strands (Figure 7C), suggesting a dis-
the signaling complexes be necessary? The CD28:B7-2 tinct arrangement of the CD28 monomers.
interaction (Kd  20 M) has similar properties to TCR- Predicting when such a rearrangement might have
and adhesion molecule (CD2)-ligand interactions; i.e., occurred in the course of the evolution of these proteins
binding is monovalent and has fast kinetics and similarly is more difficult. It is clear that CD28, CTLA-4, and ICOS
high Kd values (15–20 M; Willcox et al., 1999; van der evolved from a common precursor, as did the B7-pro-
Merwe et al., 1994). Interactions with these properties teins and LICOS. The bivalency of CTLA-4 and ICOS
are ideally suited to highly dynamic cell-cell contacts (D.W.B. and A.V.C., unpublished data) suggests that the
that will facilitate the “scanning” of cellular targets for common precursor was bivalent. However, preliminary
antigenic and adhesive ligands early in immune re- studies (D.W.B. and J.R. Young, unpublished data)
sponses (van der Merwe et al., 1995; Davis et al., 1998). showing that chicken CD28 binds monovalently to the
It is possible that the discrimination between various putative LICOS homolog, chCD80L (O’Regan et al.,
types of antigen-presenting cells, e.g., by scanning for 1999), imply that the most ancient form was monovalent
the expression of B7 molecules, is another early event (Figure 6A). Regardless of when it might have occurred,
influencing the course of T cell responses, that is likely the switch between monovalent and bivalent binding is
to be enhanced by such interactions. Naive T cells, how- likely to have had the largest single effect on the relative
ever, express relatively little CD28, and it has been sug- strength of these interactions. A structural change of
gested that B7:CD28 interactions are TCR- and immuno- this type could well have initiated the functional diversifi-
logical synapse dependent (Bromley et al., 2001). In this cation of this signaling system.
context, the very low affinity of CD28:B7-2 interactions
might instead ensure that costimulatory CD28 signaling
Experimental Proceduresdoes not preempt or overwhelm TCR responses given
that the two signaling pathways apparently intersect
Expression of sB7-2(Hehner et al., 2000). In contrast to CD28:B7-2 interac- DNA encoding the extracellular region of B7-2 (sB7-2) was amplified
tions, the combination of submicromolar affinity and by polymerase chain reaction (PCR) from cDNA prepared from MT-2
oligomeric, avidity-driven binding is thus far unique to cells. The 5 primer was complementary to the B7-2 leader sequence
B7-1:CTLA-4 interactions. The biochemistry of inhibitory (MDPQCTMG), and we added a BamHI site and inserted, immedi-
ately upstream of the initiation codon, the 25 bases that precedesignaling may require relatively prolonged receptor liga-
the rat CD4 initiation codon. The 3 primer was complementary totion to overturn ongoing activation signals. In this case,
the membrane proximal, LEDPQPPP-encoding sequence, and wethe formation of relatively few, very stable complexes
added codons encoding a tag consisting of an arginine residue
might permit efficient inhibitory signaling without com- followed by six histidines, a stop codon, and a second XbaI site.
promising the need for reversible cell-cell contact. We The PCR fragment was sequenced and subcloned into the glutamine
note that, compared to CD28:B7-2 and CTLA-4:B7-1 synthetase-based gene expression vector, pEE14, as described for
complexes, CD28:B7-1 and CTLA-4:B7-2 complexes sB7-1 (van der Merwe et al., 1997).
CHO-K1 cells were transfected using the calcium phosphatewill be intermediate in strength because CD28 is mono-
method, and clones expressing the most sB7-2 were selected byvalent and B7-2 does not self-associate (Figure 6). The
Western blotting using the ECL detection system (Amersham-Phar-formation of such complexes might be important in
macia Biotech [APB], Freiburg, Germany). The best clone was grown
allowing the intensity of costimulatory or inhibitory sig- to confluence in bulk culture before switching to fresh medium in
naling to be varied with the stage of T cell or APC differ- the presence of 2 mM sodium butyrate. The supernatant was har-
entiation. vested after approximately 4 weeks and the sB7-2 extracted by
affinity chromatography using Ni-NTA agarose (Qiagen Ltd, Crawley,Finally, the structural basis of the stoichiometric differ-
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UK). The sB7-2 was eluted from the Ni-NTA agarose with 250 mM Analytical Ultracentrifugation Methods
Sedimentation equilibrium experiments were performed in a Beck-imidazole (Sigma-Aldrich, St. Louis, MO) and further purified by
passing the protein over a HiTrap Blue column (APB) to remove man Optima XL-I analytical ultracentrifuge essentially as previously
described (Ikemizu et al., 2000). LICOS and sB7-2 were investigatedcontaminating albumin, followed by size exclusion chromatography
(Superdex 200 HR 10/30 column, APB). The extinction coefficient at a range of concentrations, and data were collected at a number
of wavelengths, ensuring linearity of absorbance:concentration. Thewas determined by amino acid analysis to be 0.904 ml/mg. Prior to
BIAcore analysis, the sB7-2 was re-passed over the Superdex 200 sample distributions measured at equilibrium were fitted with a
model for a single, ideal species. Self-association thus manifestsgel filtration column to remove aggregated protein.
as rising whole-cell molecular weights (Ikemizu et al., 2000). The
data were fitted directly to the equationGeneral SPR Experiments
Binding experiments were carried out using surface plasmon reso-
A(r)  A(rF)exp (1 
 )
2
2RT
(r2 
 r2F)  E (5)nance as implemented in the BIAcore 2000 and 3000 (BIAcore AB,
St. Albans, UK). Affinity and kinetic analyses were performed at 25C
and 37C in HBS-EP buffer (25 mM HEPES [pH 7.4], 150 mM NaCl, (where A(r) is the absorbance at radius r [in cm], A(rF) is the ab-
3.4 mM EDTA, and 0.005% surfactant P20) (BIAcore AB). For experi- sorbance at reference radius rF,  is the partial specific volume [in
ments to determine the binding affinity of sB7-2 for its ligands, ml/g], r is the solvent density [in g/ml], w is the angular velocity of
CTLA-4Fc and CD28Fc (kind gifts of P.S. Linsley), or control Fc the centrifuge rotor [in rad/sec], R is the gas constant, T is the
proteins, were indirectly immobilized to the sensor surface via the absolute temperature, and E is the baseline offset) using either the
anti-human IgG1 monoclonal antibody (r10z8e9), as previously de- nonlinear, least squares curve-fitting package Profit or the program
scribed (van der Merwe et al.,1997). The antibody (25 g/ml in 10 ULTRASPIN (D.B. Veprintsev, N.W. Foster, and A.R. Fersht, personal
mM sodium acetate [pH 4.0]) was directly immobilized to the dextran communication). The  was determined experimentally by compar-
matrix of research grade CM5 sensor chips (BIAcore AB) by amine ing the mass of a protein from MALDI-TOF mass spectrometry with
coupling using the manufacturer’s kit (BIAcore AB) and an activation its known sequence mass and was the same as that calculated
time of 5 min, resulting in immobilization levels of 750–2200 re- previously for sB7-1 (Ikemizu et al., 2000).
sponse units (RU). Following coupling, CD28Fc, CTLA-4Fc, or con-
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